Related Experiment Videos

Meningococcal disease in childhood--a regional study in Ireland

J Fogarty1, C T Keane, R Carroll

  • 1Department of Public Health, Eastern Health Board, Dublin.

Insights

Meningococcal disease in Dublin children (1981-1991) primarily affected those under 5. Vaccines for groups A and C were insufficient, highlighting the urgent need for a group B vaccine.

Area of Science:

  • Pediatric Infectious Diseases
  • Microbiology
  • Epidemiology

Background:

  • Meningococcal disease remains a significant public health concern in children.
  • Understanding the epidemiology of meningococcal disease is crucial for effective prevention strategies.
  • Previous vaccination efforts focused on specific serogroups, necessitating evaluation of their impact.

Purpose of the Study:

  • To analyze the epidemiology of culture-confirmed meningococcal disease in children under 14 in Dublin from 1981-1991.
  • To assess the potential effectiveness of existing meningococcal group A and C vaccines in preventing childhood disease.
  • To identify the need for novel vaccine development against prevalent serogroups.

Main Methods:

  • Retrospective analysis of microbiology laboratory records for pediatric meningococcal disease cases.
  • Inclusion criteria: culture-confirmed cases in children under 14 years admitted to four Dublin hospitals (1981-1991).
  • Epidemiological data analysis, including age distribution, seasonality, and serogroup prevalence.

Main Results:

  • 406 cases identified; 78.6% in children under 5 years. Meningitis predominated over septicaemia (4:1 ratio).
  • Peak incidence observed from November to March (53.2% of cases).
  • Age-specific incidence rates were highest in infants under 1 year (64.2/100,000). A rise in serogroup C disease was noted.

Conclusions:

  • Universal meningococcal group A and C immunization at 2 years would prevent only 15% of cases.
  • Current vaccination strategies are insufficient for comprehensive prevention in this pediatric population.
  • Development of a vaccine effective against meningococcal group B is urgently needed.

Related Concept Videos